Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.
Phase:
PHASE3
Details
Lead Sponsor:
First Affiliated Hospital of Guangxi Medical University
Collaborators:
The First Affiliated Hospital of University of South China The First Affiliated Hospital of Xiamen University